Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 18/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999785 | 1.00 | NPY5R (0.44) | NPY5ROPRM1SIGMAR1ADRA1AKCNH2 | |
| SCHEMBL3004565 | 0.87 | NPY5R (0.60) | NPY5ROPRM1SIGMAR1 | |
| SCHEMBL3004561 | 0.87 | NPY5R (0.60) | NPY5ROPRM1SIGMAR1 | |
| SCHEMBL3010756 | 0.85 | NPY5R (0.46) | NPY5ROPRM1SIGMAR1ADRA1AKCNH2 | |
| SCHEMBL3005653 | 0.85 | NPY5R (0.46) | NPY5ROPRM1SIGMAR1ADRA1AKCNH2 | |
| SCHEMBL3004969 | 0.85 | NPY5R (0.54) | NPY5R | |
| SCHEMBL3004972 | 0.85 | NPY5R (0.54) | NPY5R | |
| SCHEMBL3005853 | 0.85 | NPY5R (0.54) | NPY5R | |
| Hydrochloric Acid SCHEMBL3008669 | 0.84 | NPY5R (0.45) | NPY5ROPRM1SIGMAR1ADRA1AKCNH2 | |
| Hydrochloric Acid SCHEMBL3008667 | 0.84 | NPY5R (0.45) | NPY5ROPRM1SIGMAR1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | claimed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | NPY5R, NPY1R, NPY4R | NPY5R 1/4885OPRM1 63/4885SIGMAR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.